Beta Drugs (NSE:BETA) Moat Score: 0/10 (As of Jul. 06, 2026)


NSE:BETA Beta Drugs Ltd NSE:BETA
88 GF Score
Price ₹2,090.50
GF Value ₹1,970.72
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Beta Drugs Moat Score?

Beta Drugs has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Beta Drugs has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Beta Drugs might have No Moat - No discernible moat.

Beta Drugs  (NSE:BETA) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Beta Drugs Moat Score Related Terms

NSE:BETA
88GF Score
Beta Drugs Ltd NSE:BETA
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Beta Drugs (NSE:BETA) Overvalued in 2026?

Based on GuruFocus' analysis, Beta Drugs stock appears to be overvalued. The current stock price of ₹2,090.50 is trading 6.1% above its estimated GF Value™ of ₹1,970.72. GuruFocus considers Beta Drugs to be Fairly Valued.

Key valuation signals for NSE:BETA:

  • Moat Score: 0
  • GF Value™: ₹1,970.72 vs. price of ₹2,090.50 (6.1% above fair value)
  • GF Score™: 88/100 with 6 warning signs

No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beta Drugs Business Description

Address SCO-184, First Floor, Sector-5, Panchkula, HR, IND, 134114
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
88GF Score

Get the complete analysis for NSE:BETA

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,090.50
Price
₹1,970.72
GF Value